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Abstract: In spite of controversial issues, pancreatectomy following
neoadjuvant chemoradiation therapy (NeoCRT) has been applied in
treating advanced pancreatic cancer. Cases of pathological complete
remission (pCR) following NeoCRT is rare, and its long-term follow-up
data are still lacking.
From January 2000 to December 2012, medical records of the
patients who underwent pancreatectomy for pancreatic ductal adeno-
carcinoma were retrospectively reviewed. Characteristics of the patients
with pCR were summarized and their long-term follow-up data were
analyzed.
Among 86 patients with pancreatic cancer who underwent radical
pancreatectomy following NeoCRT, 10 patients (11.6%) were reported
to pCR. Nine out of 10 patients received gemcitabine-based chemor-
adiation therapy. Median pre-NeoCRT serum CA 19-9 was 313.5U/ml,
and post-NeoCRT serum CA 19-9 was 9.9U/ml, which was shown to be
significant difference between 2 serum CA 19-9 level (P¼ 0.005).
Pylorus-preserving pancreaticoduodenectomy was done in 8 patients,
and the others received distal pancreatosplenectomy. Postoperative
chemotherapy was received in 6 patients. Disease-free survival was
statistically superior in patients with pCR than patients without pCR
(P< 0.05). However, 5 patients experienced cancer recurrence and no
clinicopathologic variables including preoperative resectability could
not predict the potential recurrence of tumor in patients with pCR
(P> 0.05).
pCR is rarely reported following NeoCRT, but this condition is not
telling the cure of the disease. Early recurrence in the pattern of liver
metastasis and peritoneal seeding can be expected. However, long-term
survival could be maintained in patients without recurrence. Furtherogeun Kim, MD, ang, MD,
ng Jin Kim, MD, and Woo Jung Lee, MD
Abbreviations: NeoCRT = neoadjuvant chemoradiation therapy,
Neo-Tx = neoadjuvant therapy, pCR = pathological complete
remission, PDAC = pancreatic ductal adenocarcinoma, PV = portal
vein, SMV = superior mesenteric vein, SV = splenic vein.
INTRODUCTION
P ancreatic cancer is regarded as one of the lethal malignantdiseases arising in gastrointestinal tract. Margin-negative
resection is an essential step for cure of disease, but only 20%
of the patients with pancreatic cancer can be treated by
surgical resection.1 However, most patients who underwent
pancreatectomy usually experience tumor recurrence, especi-
ally in liver, within 2 years after surgery, resulting in disease-
specific survival, 15% to 20%.2 Therefore, surgery alone is
not enough for cure of pancreatic cancer. Postoperative
adjuvant chemotherapy should be applied for improving
oncologic outcomes. Unfortunately, it is reported as many
as 50% of the patients who underwent curative resection
of pancreatic cancer cannot receive proper postoperative
adjuvant chemotherapy due to delayed recovery and major
surgical morbidity.3
There are several rationales of neoadjuvant therapy (Neo-
Tx) in pancreatic cancer. It can convert an initial unresectable
pancreatic cancer to a resectable one. It can avoid unnecessary
laparotomy if the pancreatic cancer progresses during preo-
perative treatment. It provides complete cancer treatment in
case of surgical resection. The effect of preoperative anticancer
treatment can be enhanced because tissues are well vascular-
ized. Recent large volume series suggest that pancreatectomy
following Neo-Tx is safe and effective in treating advanced
pancreatic cancer.4,5 Oncologic role of pancreatectomy follow-
ing Neo-Tx in treating pancreatic cancer is sum of following
effects: patients selection, potential down-staging effect, and
complete cancer treatment.6
Pathologic complete remission (pCR) after Neo-Tx has
been reported in treating other gastrointestinal cancer. In rectal
cancer patients who have received Neo-Tx, approximately 15%
of the patients are reported to be pCR,7 and patients with
esophageal cancer who received Neo-Tx, up to 40% of them
have been reported to have pCR in their surgical specimens. It
was shown that pCR improved oncologic outcomes including
lower incidence of local recurrence, distant metastasis, and
better survival rate.8
However, there are a few case reports on pCR following
Neo-Tx in treating pancreatic cancer.9 According to literatures,
about 1.3% to 7% of the patients with pancreatectomy following
Neo-Tx are reported to be complete remission (pT0).4,5 TheR in pancreatic cancer is not still clearly
y, we identified 9 patients with pCR
o underwent pancreatectomy following
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Neo-Tx for pancreatic cancer. We investigated prognostic
impact of pCR on oncologic outcome of the pancreatic cancer.
MATERIALS AND METHODS
Patients and Data Collection
This study was approved by the Institutional Review Board
of Severance hospital. From January 2000 to December 2012,
we retrospectively evaluated the patients who underwent sur-
gical resection following neoadjuvant treatment for pancreatic
cancer from our cohort database. Demographic and clinico-
pathologic factors were acquired from database and the infor-
mation for disease-free and disease-specific overall survival
period were also included.
Neoadjuvant Treatment for Pancreatic Cancer
Neoadjuvant treatments were applied for borderline
resectable pancreatic cancer inmost cases. After the pathologic
confirmation regarding pancreatic ductal adenocarcinoma
using cytology via endoscopic retrograde cholangiography,
Lee et alpatients received gemcitabine-based chemotherapy including
or not additional radiotherapy of which total radiation dose
was usually from 5040 to 6000 cGy. Pancreatectomy was
FIGURE 1. Clinical feature of pathologic complete remission of pancre
with SMA abutment before Neo-Tx, (B) shrunk uncinate mass after Ne
steep decline of CA 19-9 level after Neo-Tx. NeoCRT, neoadjuvant
2 | www.md-journal.comperformed after evaluation for treatment effect in radiologic
evaluations.
Statistics
All statistical analyses were performed by using IBM1
SPSS1 Statistics version 20. Continuous variables were indi-
cated as mean standard deviation or range and categorical
variables as frequency and percentage. Student t test and
Mann–Whitney U test were used for comparing continuous
variables between pCR and non-pCR group and Chi-square
and Fisher exact were used for comparing categorical data
between 2 groups. Kaplan–Meier method was applied for survi-
val analysis of disease-free and disease-specific overall survival
period. P-value< 0.05 was considered as statistical significance.
RESULTS
Patients Demographics of PCR Confirmed by
Pancreatectomy Following Neo-CRT
Among 86 patients who underwent pancreatectomy fol-
Medicine  Volume 94, Number 52, December 2015lowing Neo-CRT, 9 patients (10.4%) were reported to have no
residual pancreatic cancer cells in final pathologic examination
(Figure 1, Table 1). Six patients were female and 3 were male
atic cancer after NeoCRT. (A) Pancreatic cancer in uncinate portion
o-Tx, (C) no residual cancer cell in pathologic examination, (D) a
chemoradiation therapy; SMA, superior mesenteric artery.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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with median age, 64 (range, 55–74) years. Most patients (8 out
of 9 patients) received gemcitabine-based chemotherapy or
chemoradiation therapy. Initial CA 19-9 was noted to be
685.1 1024.7, which was decreased to 20.1 30.1 following
neoadjuvant chemoradiation therapy (NeoCRT) (P¼ 0.008).
Ten patients had pancreatic head cancer requiring pancreati-
coduodenectomy. Five patients required combined venous vas-
cular resection such as 4 segmental resections of SMV-SV-PV
confluence and 1 wedge resection of SMV.
Comparison of Clinicopathologic Factors
Between pCR and Non-pCR
In comparative analysis, there were no clinicopathologic
Lee et aldifferences between pCR and non-pCR group (P> 0.05), how-
ever, CA19-9 after Neo-CRT (P¼ 0.053), pT stage (P< 0.001),
and pN stage (P¼ 0.024) were significantly different between 2
TABLE 2. Comparison of Clinicopathologic Factors Between pCR
Variables pC
Age 62
Gender Female
Male
Symptom No
Yes
Tumor size cm 3
CA19-9 Before Neo-Tx 685.
After Neo-Tx 20
Resectability Resectable
Borderline resectable
Locally advanced
Tumor location Head
Body
Tail
Body-Tail
Operation PD
PPPD
DPS
TP
Combined VVR No
Yes
pT stage T0
T1
T2
T3
T4
pN stage N0
N1
EBL 705
Transfusion No
Yes
POAT No
Yes
Morbidity No
Yes
Mortality No
Yes
DPS¼ distal pancreatectomy with splenectomy; EBL¼ estimated blood
treatment; PPPD¼ pylorus preserving pancreaticoduodenectomy; TP¼ to
venous vascular resection.
4 | www.md-journal.comgroups (Table 2). During follow-up period (median 21 months
(range, 10–63)), 4 patients experienced tumor recurrence (2 in
liver and 2 in peritoneum), and the rest 5 patients (5.8%, 5 out of
86) still have no evidence of tumor recurrence in pCR group.
Most recurrence was found within 1 year after surgery. Among
them, 4 patients have been in disease-free condition for more
than approximately 3 years. There was no difference in disease-
free survival (mean 37.1 months vs. 25.3 months, P¼ 0.269)
between 2 groups (Figure 2A). Disease-specific survival in pCR
group was shown to be superior to that of non-pCR group with
marginal significance (mean, 56.3 months vs. 41.9 months,
P¼ 0.066), Figure 2B.
Medicine  Volume 94, Number 52, December 2015DISCUSSION
The current results showed that even 4 patients with pCR
showed systemic recurrence in liver and peritoneum within 1
and Non-pCR
R (n¼ 9) Non-pCR (n¼ 77) P-Value
.8 8.2 60.4 9.7 0.483
6 30
3 47 0.156
2 13
7 64 1
.1 1.6 2.9 0.9 0.412
1 1024.1 1132.4 2334.3 0.573
.1 30.1 206.9 767.4 0.052
2 35
5 28
2 14 0.385
7 60
1 10
1 5
0 2 0.696
0 8
7 51
2 17
0 1 0.88
5 52
4 25 0.478
10 0
11
5
60
1 <0.001
9 47
0 30 0.024
.5 834.7 1023.2 835.0 0.286
7 39
2 37 0.17
3 26
6 50 0.714
3 42
6 35 0.299
9 76
0 1 1
loss; PD¼ pancreaticoduodenectomy; POAT¼ postoperative adjuvant
tal pancreatectomy; pCR¼ pathological complete remission; VVR¼
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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possible reason may be resulted from pathological underesti-
mation or inaccurate assessment of treatment effect of Neo-Tx.
There are proposed several grading systems to assess the
treatment effect of Neo-Tx in pancreatic cancer by Ishikawa
et al,10 Evans et al,11 Pendurthi et al,12 and White et al.13
Essentially, these grading schemes are dealing with one of the 3
variables: viable tumor cell mass, fibrosis, and/or necrosis, but
providing inconsistency and controversy in determining treat-
ment effect of Neo-Tx. For example, according to the original
descriptions of tumor response from Evans scheme,11 pCR may
represent nonviable tumor cells as grade IV response. Nonvi-
able tumor cells were characterized as ‘‘cells with bizarre,
hyperchromatic, or pyknotic nuclei, usually associated with
markedly swollen, vacuolated or deeply eosinophilic cyto-
plasm.’’10 It is extremely difficult to determine the viability
of residual carcinoma cells based on morphologic features in
clinical practice.14 Routine hematoxylin and eosin staining-based
pathological examinationmaynot detect potential residual cancer
cell in resected specimen. In addition, there is still no world
widely accepted standardized protocol in handling pancreatec-
tomized specimen of pancreatic cancer, and the protocols for
pathological examination in pancreatectomized specimen seem
to vary from institutions to institutions. It may depend on
individual pathologists’ insight and effort to accurately assess
treatment effect of Neo-Tx in pancreatic cancer.
Therefore, there is potential room for not detecting residual
cancer cells in routine pathological examinations, which later
resulting in treatment failure even in cases of pCR. In fact,
considering relative low incidence of pCR4,5 in reported litera-
tures, 10.5% incidence of pCR looks high in present study (9 out
of 86 patients).
Another potential mechanism of tumor recurrence after
confirming pCR can be explained as follow; pancreatic cancer
may be systemic disease from the beginning. Although pancrea-
FIGURE 2. Oncologic outcome of pancreatectomy following Neo
groups by Kaplan–Meier method (P¼0.269), (B) comparisons of d
pCR, pathological complete remission.tic cancer cells in resected specimen were all destroyed due to
Neo-Tx, metastatic foci refractory to conventional treatment
might still exist and cause subsequent recurrence during the
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.follow-up period. As shown in present data, 2 recurrences were
found as hepatic metastasis and the rest two as peritoneal
seeding, supporting this postulation.
Therefore, even patients with pCR who underwent radical
pancreatectomy following Neo-Tx need to receive postopera-
tive adjuvant chemotherapy. Considering viable metastatic
tumor cells resistant to previous Neo-Tx, additional new com-
bination of chemotherapeutic agent would be ideal in this
setting, which will be further investigated in clinical oncology.
Most recurrence was found within 1 year after surgery,
however, it should be noted that patients with pCR who did not
experience tumor recurrence remains in disease-free condition.
Five patients (5.8%, 5 out of 86) still have no evidence of tumor
recurrence in pCR group. Among them, 4 patients have been in
disease-free condition for more than approximately 3 years.
Aside from potential contamination of undetected residual
cancer cells and systemic nature of disease in pCR group, this
observation is strongly suggesting pCR, it is real in clinical
setting of Neo-Tx for pancreatic cancer. Zhao et al15 recently
reported that 100% of disease-specific overall survival in
patients with pCR (n¼ 10), which showing a significant better
than those of posttreatment stage I or stage IIA disease in
resected pancreatic cancer following Neo-Tx (P< 0.001). Their
reported incidence of pCR is 2.5% indirectly shows strict and
meticulous evaluation of pathologic examination of resected
specimen. In present study, it was observed that disease-specific
survival in pCR group was shown to be superior to that of non-
pCR group with marginal significance (mean, 56.3 months vs.
41.9 months, P¼ 0.066), but when considering pure pCR
candidates, there are significant survival difference between
2 groups (P< 0.05, data not shown).
Retrospective study design and small number of patients
with pCR are inevitable limitations in our study. And, study
period was relatively long and a number of pathologists were
involved in pathologic examination for pancreatectomy speci-
T. (A) Comparisons of disease-free survival of pCR and non-pCR
se-specific overall survival of pCR and non-pCR groups (P¼0.066).men. Nevertheless, this study can be valuable evidence for
evaluating clinical meaning of pCR following neoadjuvant
treatment in pancreatic cancer in limited clinical references.
www.md-journal.com | 5
In conclusion, pCR can be achieved from neoadjuvant
treatment in pancreatic cancer. Postoperative adjuvant treat-
ment, however, may be required even in pCR because pCR can
be contaminated with potential residual cancer cells and pan-
creatic cancer is systemic disease which can have metastatic
foci in early phase. Further investigation for predicting failure
of neoadjuvant treatment is mandatory.
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